Fabrice Egros - May 18, 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
May 18, 2021
Transactions value $
-$154,654
Form type
4
Date filed
5/20/2021, 04:46 PM
Next filing
Aug 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $85.9K +11.9K +74.54% $7.20 27.9K May 18, 2021 Direct
transaction SNDX Common Stock Options Exercise $13.3K +1.68K +6.03% $7.88 29.6K May 18, 2021 Direct
transaction SNDX Common Stock Sale -$222K -11.9K -40.28% $18.65 17.7K May 18, 2021 Direct F1
transaction SNDX Common Stock Sale -$31.4K -1.68K -9.52% $18.65 16K May 18, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -1.68K -100% $0.00* 0 May 18, 2021 Common Stock 0 $7.88 Direct F2
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -11.9K -100% $0.00* 0 May 18, 2021 Common Stock 0 $7.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 93,317 options to purchase shares of common stock that are vested and immediately exercisable and a total of 0 options to purchase shares of common stock that have not yet vested.
F2 This option is fully vested.